A few days ago, the projective infrared vascular imaging instrument successfully developed by Xi’an Institute of Optics and Precision Mechanics of CAS and its joint-stock company Shimmer Medical Devices Technology Co., Ltd. of CAS was approved by China Food and Drug Administration and has been brought to the market officially. The said innovative product can solve the difficulty about finding vascular of patients during acupuncture and puncture treatment and is expected to replace the traditional method of puncture by naked eyes, which brings a transformation in health care field.
With the improvement of living standard, increasing of obese patients, high precise requirements of infants and ICU patients to acupuncture and puncture skills of medical care personnel, as well as the fragile physician-patient relationship, patients become sensitive to the condition that they are acupunctured many times or even fail to be acupunctured. R&D Team from Xi’an Institute of Optics and Precision Mechanics of CAS, inspired by aerospace imaging technology and with innovative ideas, successfully developed projective infrared vascular imaging instrument and solve the acupuncture problem for obese patients and infants.
Projective Infrared Vascular Imaging Instrument System
The stereo imaging equipment developed by XIOPM was successfully applied to China's Chang’e-1 and Chang’e-2 lunar probe and successively acquired the most completed and most clear full moon image in the world. The scientific researchers, not only make their efforts to make contribution to China’s aerospace industry, but also bend themselves to industrialization exploration to make general aerospace imaging technology to be applicable to livelihood field. Within less than 4 months, the researchers successively overcame infrared illumination, embedded design, deep vascular algorithm optimization and other difficulties, which realized breakthrough of R&D speed, image definition and real-time vascular setting accuracy.
Based on the introduction of Zhu Rui, the principal of R&D Team, projective infrared vascular imaging instrument mainly takes advantage of the different absorption rate of hemoglobin in the vascular to near-infrared light with other tissue, through a series of digital image processing, making the normal position of subcutaneous vascular projection display on skin surface, so the physicians are able to recognize the 8-10mm small capillaries of subcutaneous clearly. Since the said product adopts mature DLP projection program of TI Company, in addition, it is distinguished from infrared light projection model in current market (notes: most of the congeneric products in current market adopts laser projection), which makes it win out over international congeneric products (those of America etc.) in both service performance and operational safety. The product has been introduced into Chinese PLA General Hospital (301 Hospital), the Second People’s Hospital of Shenzhen and other units and is favored by health care personnel for its easy to use and precise image features.
Real Time Imaging Effect Picture
Benefited from aerospace imaging technology, the new generation projective infrared vascular imaging instrument, being the 1st batch go-on-sale product jointly developed and produced by XIOPM and Shimmer Medical Devices Technology Co., Ltd. of CAS, is an iconic milestone. Up to now, Shimmer Medical Devices Technology Co., Ltd. of CAS has established strict management and fine production line in accordance with National Medical Devices Industry standards ISO13485 so as to escort for mass production of company products. XIOPM and Shimmer Medical Devices Technology Co., Ltd. of CAS will capitalize on the sales of the said product to continue scientific research breakthrough and product innovation and make great contribution to China’s high-end medical optical imaging technology and national medical health.
Shimmer Medical Devices Technology Co., Ltd. of CAS, with XIOPM holding stock, is a high-tech medical imaging technology enterprise specializing on systems R&D, production and sales of ophthalmology, cardiovascular and endoscopic optical coherence tomography (OCT). The company was found in August 2012 with founding team from members of CAS, the University of Hong Kong, Tsinghua University and other scientific research institutions. At present, the company has more than 20 team members in total, including 2 doctors, 3 masters and 12 undergraduates. The company has the capacity to conduct R&D and production of many OCT core technologies and critical core parts. Its vision is, by means of vertical integration mode, to become an OCT imaging company with the ability to produce not only core parts but also complete machine system, and a world-class and leading OCT optical imaging technology company in China, to make outstanding contribution to progress of China’s high-end optical medical imaging technology and national medical health.
